Athersys Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
30,743.00
22,082.00
16,422.00
15,337.00
32,241.00
24,283
Depreciation, Depletion & Amortization
346.00
360.00
267.00
382.00
684.00
855
Other Funds
7,854.00
4,179.00
2,157.00
2,553.00
5,444.00
4,627
Funds from Operations
22,543.00
25,901.00
13,975.00
12,400.00
26,113.00
18,801
Changes in Working Capital
241.00
110.00
211.00
1,469.00
2,095.00
5,451
Net Operating Cash Flow
22,784.00
25,791.00
13,764.00
10,931.00
24,018.00
13,350
Capital Expenditures
385.00
297.00
132.00
1,711.00
285.00
Purchase/Sale of Investments
-
-
-
38.00
-
Net Investing Cash Flow
385.00
297.00
132.00
1,067.00
285.00
Net Financing Cash Flow
29,584.00
20,267.00
10,796.00
3,724.00
38,866.00
Net Change in Cash
6,415.00
5,821.00
3,100.00
8,274.00
14,563.00
Free Cash Flow
23,169.00
26,088.00
13,896.00
12,642.00
24,303.00
Deferred Taxes & Investment Tax Credit
-
-
23.00
2.00
-
-
Other Sources
-
-
-
682.00
-
Change in Capital Stock
29,584.00
20,267.00
10,796.00
3,724.00
38,866.00

About Athersys

View Profile
Address
3201 Carnegie Avenue
Cleveland Ohio 44115
United States
Employees -
Website http://www.athersys.com
Updated 07/08/2019
Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J.